Hospitals
Medical Offices/Clinics
Interactive Map
Physician Publications
Lee Rosen, MD, FACP is Health Sciences Clinical Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine. He has a longstanding interest in the treatment of pancreas and other gastrointestinal malignancies, specifically in the area of new drug development. Dr. Rosen completed his residency and fellowship in hematology/oncology at the UCLA School of Medicine in 1996, joining the full-time faculty immediately thereafter. He created and directed the Cancer Therapy Development Program, designed to coordinate translational/clinical research of new cancer treatments. Some of the first drugs he and his team worked with were designed for gastrointestinal cancers, so he and colleagues created a group dedicated to treating these diseases in a coordinated fashion. He also became interested in so-called "targeted" therapy, whereby cancers could be attacked by agents with a more rational drug design and the avoidance of toxicity to normal cells. He has worked with angiogenesis inhibitors since their first appearance in the clinic and other molecules inhibiting signal transduction, others that try to harness the immune system to control cancer and still others that work by rational drug design.
Dr. Rosen and his group recently rejoined the Division of Hematology-Oncology at UCLA in 2011, where he now directs our Drug Development Program, co-directs the outpatient cancer center in Santa Monica and participates actively in the Gastrointestinal Malignancy multi-specialty groups. He continues his active clinical practice and his search for new, hopefully less toxic and more effective ways of treating cancers. His many clinical trials are open to patients with a range of malignancies and there are many new trials coming soon.
Board-certified in Internal Medicine and Medical Oncology, trained in Hematology, Dr. Rosen is also a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the American Society of Hematology (ASH) and the American College of Physicians (ACP, where he is also a Fellow).
